Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EEF2K | O00418 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482538 | 0.76 | GAA (0.45) | GAACNR2CES2CES1LMNA | |
| SCHEMBL15317055 | 0.75 | EEF2K (0.43) | GAACNR2CES2CES1LMNA | |
| SCHEMBL8750846 | 0.75 | MEN1 (0.47) | GAACNR2CES2CES1LMNA | |
| SCHEMBL6120380 | 0.75 | MEN1 (0.47) | GAACNR2CES2CES1LMNA | |
| SCHEMBL23886688 | 0.75 | GAA (0.44) | GAACNR2CES2CES1LMNA | |
| Hydrochloric Acid SCHEMBL2485774 | 0.75 | GAA (0.44) | GAACNR2CES2CES1LMNA | |
| SCHEMBL23886691 | 0.75 | GAA (0.44) | GAACNR2CES2CES1LMNA | |
| SCHEMBL21279857 | 0.74 | GAA (0.44) | GAACNR2CES2CES1LMNA | |
| SCHEMBL5645158 | 0.71 | CNR2 (0.50) | GAACNR2CES2CES1LMNA | |
| SCHEMBL5645167 | 0.71 | CNR2 (0.50) | GAACNR2CES2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | GAA 61/4885CNR2 4608/4885CES2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.